US President Barack Obama with Indian Prime Minister Manmohan Singh. Official White House Photo by Pete Souza
India’s drug patent policy has been slammed by US companies who are insisting that action be taken in order to improve trade relations.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pharmaceuticals, Drugs, evrgreening, compulsory licence, India, US, Novartis, Bayer, Roche, AFTI